Publications

• PSA response to cabazitaxel is associated with improved progression-free survival in metastatic castration-resistant prostate cancer: the non-interventional QoLiTime study

  R. D. Hofheinz, C. Lange, T. Ecke, S. Kloss, B. Linsse, C. Windemuth-Kieselbach, P. Hammerer, S. E. Al-Batran

  PMID: 29305637 Show Details link to full text
  Study

  QoLiTime

  Year

  2018

  Keywords

  • cabazitaxel
  • prostate cancer
  • oncology

• Effects of dapagliflozin on insulin-requirement, glucose excretion and ß-hydroxybutyrate levels are not related to baseline HbA1c in youth with type 1 diabetes.

  T.Biester, B. Aschemeier, M. Fath, M. Frey, M. F. Scheerer, O. Kordonouri, T. Danne

  PMID: 28417527 Show Details link to full text
  Study

  DAPA IIT179

  Year

  2017

  Keywords

  • dapagliflozin
  • type 1 diabetes

• The HER2 phenotype of circulating tumor cells in HER2-positive early breast cancer: A translational research project of a prospective randomized phase III trial

  B. A. S. Jaeger BAS, J. Neugebauer, U. Andergassen, C. Melcher, F. Schochter, D. Mouarrawy, G. Ziemendorff, M. Clemens, V. E. Abel, G. Heinrich, K. Schueller, A. Schneeweiss, P. Fasching, M. W. Beckmann, C. Scholz, T. W. P. Friedl, K. Friese, K. Pantel, T. Fehm, W. Janni, B. Rack

  PMID: 28586395 Show Details link to full text
  Study

  SUCCESS B

  Year

  2017

  Keywords

  • HER2
  • breast cancer
  • oncology

• Quality of life and pain relief in men with metastatic castration-resistant prostate cancer on cabazitaxel: the non-interventional 'QoLiTime' study

  R. D. Hofheinz, C. Lange, T. Ecke, S. Kloss, B. Linsse, C. Windemuth-Kieselbach, P. Hammerer, S. E. Al-Batran

  PMID: 27618249 Show Details link to full text
  Study

  QoLiTime

  Year

  2017

  Keywords

  • cabazitaxel
  • mCRPC
  • QoL
  • oncology

• PARP Inhibitors for Recurrent Ovarian Carcinoma: Current Treatment Options and Future Perspectives

  J. Sehouli, E. I. Braicu, R. Chekerov

  PMID: 26941449 Show Details link to full text
  Study

  Year

  2016

  Keywords

  • PARP inhibitors
  • ovarian cancer
  • oncology

• Phase II DeCOG-study of ipilimumab in pretreated and treatment-naïve patients with metastatic uveal melanoma.

  L. Zimmer, J. Vaubel, P. Mohr, A. Hauschild, J. Utikal, J. Simon, C. Garbe, R. Herbst, A. Enk, E. Kämpgen, E. Livingstone, L. Bluhm, R. Rompel, K. G. Griewank, M. Fluck, B. Schilling, D. Schadendorf

  PMID: 25761109 Show Details link to full text
  Study

  Multibasket/DeCOG

  Year

  2015

  Keywords

  • uveal melanoma
  • ipilimumab
  • oncology

• Therapieinnovation: Der PARP Inhibitor Olaparib, Diagnostik und Therapie

  J. Pfisterer, F. Hilpert, A. du Bois

  PMID: Show Details link to full text
  Study

  Year

  2015

  Keywords

  • ovarian cancer
  • Olaparib
  • PARP inhibitors
  • oncology

• Biweekly Cetuximab Plus FOLFOX6 as First-Line Therapy in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The CEBIFOX Trial

  S. Kasper, J. Meiler, H. Knipp, T. Höhler, P. Reimer, T. Steinmetz, W. Berger, G. Linden, H. Reis, P. Markus, A. Paul, A. Dechêne, B. Schumacher, K. Kostbade, I. Virchow, S. Ting, K. Worm, K. W. Schmid, T. Herold, M. Wiesweg, M. Schuler, T.Trarbach

  PMID: 26637909 Show Details link to full text
  Study

  CEBIFOX

  Year

  2015

  Keywords

  • BRAF mutation
  • metastatic colorectal cancer
  • RAS mutation
  • cetuximab
  • oncology

• Treosulfan in the Treatment of Advanced Ovarian Cancer - Results of a German Multicenter Non-interventional Study

  R. Chekerov, G. Kaltenecker, D. Reichert, T. Göhler, P. Klare, G. Oskay-Özcelik, U. Sauer, A. Wischnik, U. Vehling-Kaiser, M. Becker, U. Hutzschenreuter, A. Ammon, E. Heidrich-Lorsbach, J. Sehouli

  PMID: 26637909 Show Details link to full text
  Study

  Year

  2015

  Keywords

  • Treosulfan
  • ovarian cancer
  • oncology

• The impact of docetaxel-related toxicities on health-related quality of life in patients with metastatic cancer (QoliTax).

  S. E. Al-Batran, W. Hozaeel, F. K. Tauchert, R. D. Hofheinz, A. Hinke, C. Windemuth-Kieselbach, A. Hübner, M. Burmester, M. Koenigsmann, J. Wiegand, G. Zur Hause, B. Linsse, R. Kuhl, C. Pauligk

  PMID: 25755108 Show Details link to full text
  Study

  QoliTax

  Year

  2015

  Keywords

  • docetaxel
  • metastatic colorectal cancer
  • QoL
  • oncology
  • HRQoL